Forecast
The analysts' average price target is €8.66 (+368.11%). The median is €8.66 (+368.11%).
| Buy |
Â
2 |
| Hold |
Â
3 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
XenoTherapeutics completes acquisition of ESSA Pharma
XenoTherapeutics has completed the acquisition of ESSA Pharma and acquired all outstanding common shares through its subsidiary Xeno Acquisition Corp. for about $0.1242 per share. The previously revised terms were supplemented by a contingent value right (CVR) that can enable additional payments of up to $0.14 per share and up to $6.7 million in total. The acquisition was approved by the Supreme Court of British Columbia; ESSA has applied to delist from Nasdaq and plans an $80 million liquidation distribution to shareholders. » More on de.investing.com
ESSA Pharma shareholders approve takeover by XenoTherapeutics
Holders of ESSA Pharma securities voted by an overwhelming majority (99.83% and 99.85% including options/warrants) to approve the takeover by XenoTherapeutics under a plan of arrangement. The transaction remains subject to court approval by the Supreme Court of British Columbia; the hearing is scheduled for October 7, 2025, and closing is expected around October 9, 2025. ESSA announced amended deal terms: the expected cash payment was reduced from 1.91 USD to about 0.12 USD per share, and shareholders will also receive a non-transferable CVR with a possible payment of up to 0.14 USD; additionally, an $80 million distribution to shareholders is planned. Shareholders also provisionally approved a voluntary liquidation in case the takeover fails and voted to approve the transaction-related compensation for executives. » More on de.investing.com
ESSA Pharma gets court approval for meeting date for takeover by XenoTherapeutics
The Supreme Court of British Columbia approved the rescheduling of ESSA Pharma’s extraordinary general meeting to Oct. 3, 2025 as an online webcast; stakeholders can object until Oct. 1, and court approval of the deal is set for Oct. 7. XenoTherapeutics is to acquire all issued common shares of ESSA, but the merger terms were revised: the expected cash payout was cut from about $1.91 to roughly $0.12 per share and a non‑transferable CVR worth up to $0.14 was added. ESSA plans an $80m distribution to shareholders (payment date Aug. 22) and the acquisition financing comes from XOMA Royalty Corporation. The micro‑cap stock is trading near its 52‑week low and is down 74% year to date. » More on de.investing.com
ESSA Pharma: changed merger terms drastically cut payout forecast, stock falls 17%
ESSA Pharma adjusted the terms of the merger with XenoTherapeutics, reducing the expected per-share payout from about $1.91 to roughly $0.12. Additionally, contingent value rights of up to $0.14 per share are to be issued, with payouts tied to specific events. The company cites updated cash estimates and potential liabilities as reasons; XOMA Royalty remains structuring agent and intends to finance the transaction. The stock fell 17% in premarket trading. ESSA postponed the special shareholder meeting to October 3 and will report the change in a Form 8‑K. » More on de.investing.com
ESSA Pharma cuts payouts in amended merger agreement with XenoTherapeutics
ESSA Pharma has amended the terms of its takeover by XenoTherapeutics, reducing the cash payment at closing from about $1.91 to roughly $0.12 per share. In addition, shareholders will receive one non-transferable CVR per share with a potential additional payout of up to about $0.14 per CVR. The company cites potential liabilities, related costs and current cash balance forecasts as reasons; the extraordinary general meeting has been postponed to October 3. XOMA Royalty Corporation remains structuring adviser and financier of the transaction; InvestingPro considers ESSA undervalued at its current market capitalization. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2025, ESSA Pharma Inc has already paid €1.44 in dividends. The last payout was in August 2025.
Financials
In the last quarter, ESSA Pharma Inc had revenue of €0 and net profit of -€3.4m
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -13.9k | - |
| Net profit | -3.4m | - |
| EBITDA | -4.22m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.67m |
Number of shares | 47.31m |
52-week high/low | €5.88 - €0.16 |
| Dividends | No |
Beta | 1.53 |
P/E ratio | -0.31 |
PEG ratio | -0.04 |
P/B ratio | 0.07 |
P/S ratio | 0.00 |
Company profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
| Name | ESSA Pharma Inc |
| CEO | David Ross Parkinson |
| Headquarters | Vancouver,
bc Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 13/03/2015 |
| Employees | 35 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | EPIX |